iwCLL

1-888-476-9129 info@bioascend.com

Menu

 

Press

FOR IMMEDIATE RELEASE  

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Announces Call for Abstracts for Upcoming Biennial Meeting, May 12-15, 2017

NEW YORK, NY, November 21, 2016 — Today, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) announced that the call for abstracts is open for the 17th biennial meeting, taking place May 12-15, 2017 in New York City. All submissions including original work, late-breaking data, trials in progress, and encore studies will be reviewed and considered for inclusion in the iwCLL 2017 meeting as either a poster, an oral presentation, and/or for the Young Investigators Meeting (YIM) program. YIM abstracts will be accepted through January 15 and general abstracts for iwCLL will be accepted through January 30. 

The iwCLL is the largest international organization focused solely on advancing the understanding and treatment of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders. Additionally, the YIM forum – which will be held on May 12 – permits young investigators (less than 40 years of age) to present and discuss their data with today’s CLL experts. The iwCLL 2017 meeting will be organized around the following themes in the field of CLL and related blood-disorders:

•  Factors contributing to the development of CLL

•  Diagnosis, prognosis and initial treatment of CLL

•  Mechanisms leading to disease progression and evolution

•  Therapy for advanced disease

“We are looking forward to another successful meeting with many opportunities to hear about the latest ideas in the field and to initiate collaborations among investigators worldwide,” said Nicholas Chiorazzi, MD, Meeting and Program Chair. “Our goals for iwCLL are to spur the continued development of today’s research and spark new ideas among clinic- and laboratory-based scientists that could lead to an elimination of this still incurable disease.”

For more information on submitting abstracts, visit Call for Abstracts on the iwCLL website at www.iwCLL2017.org.

 

About International Workshop on Chronic Lymphocytic Leukemia

Founded in 1979, iwCLL is now the largest international meeting dedicated to advancing state-of-the-art and emerging concepts – from laboratory-based research to the clinic – relating to the pathobiology and treatment of this blood cancer. The biennial meeting provides a forum that promotes the exchange of information and encourages collaboration among international leaders and scientists interested in CLL and lymphoproliferative disorders. For more information about iwCLL, visit the website at www.iwCLL2017.org or connect with us on Twitter (@iwCLL), Facebook, or LinkedIn.

For Media Inquiries Contact: iwCLL2017@bioascend.com

 

 

FOR IMMEDIATE RELEASE   

The International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Announces 2017 Biennial Meeting Dates and Focus

NEW YORK, NY, July 6, 2016—Today, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) released the dates and themes for the upcoming 2017 iwCLL congress. The largest international organization focused solely on advancing the understanding and treatment of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders, iwCLL will hold its 17th biennial assembly May 12-15, 2017 at the New York Marriott Marquis Times Square.

“The iwCLL congress is intended to provide a forum for promoting the exchange of information and encouraging collaboration among international leaders and scientists, from laboratory-based research to the clinic,” said Nicholas Chiorazzi, MD, Meeting and Program Chair. “Each opportunity we have to share the latest thinking and make connections with others in the field can generate new ideas that will ultimately lead to an elimination of this still incurable disease. The iwCLL 2017 meeting is a forum designed to do exactly that.”

In 2017, the iwCLL program and special sessions will be organized around the following themes:

  • Emerging evidence regarding factors that contribute to the development of CLL
  • Emerging evidence regarding the diagnosis, prognosis, and intial treatment of CLL
  • Emerging evidence regarding factors that contribute to the disease evolution and progression
  • Emerging evidence regarding therapy for advanced disease

The abstract deadline is January 30, 2017. All submissions of original work will be reviewed and considered for inclusion in the program as an oral presentation or as a poster at the main meeting and/or at the Young Investigators Meeting (YIM) on May 12, 2017.

 

For more information on how to attend or participate, visit the iwCLL website at www.iwCLL2017.org, email meetings@bioascend.com, or connect with us on Twitter (@iwCLL), Facebook, or LinkedIn.

For Media Inquiries Contact:

iwCLL2017@bioascend.com